In September 2014, we entered into an Exclusive Channel Collaboration (ECC) agreement with Intrexon. This agreement provides for our worldwide exclusive use of Intrexon’s proprietary synthetic biology technology platform for the development and commercialization of genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Through the ECC, Histogenics will employ its expertise in novel solutions for musculoskeletal-related conditions, and Intrexon will utilize several of its integrated technologies to develop a universal allogeneic cell treatment for cartilage repair. Leveraging its UltraVector® platform for gene program design plus its proprietary cell substrates and cell engineering technologies, including LEAP® cell processing, AttSite® recombinases and bioactive RNAs, Intrexon’s tool-kit is aptly positioned to engineer an off-the-shelf allogeneic chondrocyte cell line with multigenic modulation for immune system compatibility. The target of this ECC is the design and manufacture of next-generation cartilage tissue products that integrate with Histogenics’ proprietary cellular scaffold platforms and manufacturing processes similar to those currently deployed in their ongoing NeoCart® Phase 3 trial. We believe this arrangement will enable us to develop potential next-generation cartilage products, increase our future manufacturing capacities and efficiencies, and accelerate our platform technology pipeline initiatives.
View more about Intrexon on their website.
If you are interesting in partnering opportunities with Histogenics, please email us at InvestorRelations@histogenics.com